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EDITORIAL
The US Chinese Anti-Cancer Association 
and the Asian Fund for Cancer Research 
Recognize Young Chinese Cancer Researchers 
with the 2016 USCACA–AFCR scholar awards
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To foster and strengthen collaborations among can-
cer researchers and physicians in the United States 
(US) and China, the US Chinese Anti-Cancer Asso-
ciation (USCACA), the National Foundation for Can-
cer Research (NFCR), and the Asian Fund for Cancer 
Research (AFCR) have established the USCACA–NFCR/
AFCR Scholarship Program in Basic, Translational, and 
Clinical Studies. Between 2010 and 2015, 24 junior Chi-
nese cancer researchers and physicians have been recog-
nized by this award for their outstanding achievements 
in cancer research accomplished both during their train-
ing in the US and after their returning to China [1–4]. In 
2016, three young researchers were selected on the basis 
of their significant contributions in translational cancer 
research. The USCACA and AFCR proudly presented the 
Award to the following three outstanding young scien-
tists during the 5th Guangzhou International Symposium 
on Oncology held in Guangzhou, Guangdong, China, 
December 1–3, 2016 (Fig. 1).
  • Dr. Song Gao, Department of Pancreatic Cancer, 
Tianjin Medical University Cancer Institute and Hos-
pital, Tianjin, China
  • Dr. Jianhua Zhou, Department of Ultrasound, Sun 
Yat-sen University Cancer Center, Guangzhou, 
Guangdong, China
  • Dr. Xiang Zhou, Cancer Institute in Shanghai Cancer 
Center, Fudan University & Institute of Biomedical 
Sciences, Shanghai, China
The three winners of the 2016 USCACA–AFCR 
Scholar Awards were invited to an award ceremony at 
the opening ceremony of the 5th Guangzhou Interna-
tional Symposium on Oncology on December 2, 2016 
in Guangzhou, China. All awardees have received excel-
lent doctoral and/or postdoctoral training under their 
US mentors who are leading cancer researchers and 
USCACA members. The discoveries and findings from 
these talented young scientists have not only significantly 
enhanced our understanding of the complex mechanisms 
underlying the development and progression of human 
cancers but also provided critical insights for identifying 
novel targets and developing new approaches for improv-
ing treatment and clinical care of cancer patients.
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The 2016 USCACA–AFCR scholars
Dr. Song Gao is currently 
an attending physician in 
the Department of Pancre-
atic Cancer at Tianjin 
Medical University Cancer 
Institute & Hospital. He 
received his Ph.D. degree 
in oncology in 2015 from 
Tianjin Medical University. 
Dr. Gao became a faculty 
at Tianjin Medical Univer-
sity Cancer Institute & 
Hospital in 2009. He joined 
Professor Wei Zhang’s lab-
oratory in the Department of Pathology at the M.D. 
Anderson Cancer Center, University of Texas, Houston, 
TX, USA as an exchange Ph.D. student in 2013. During 
his PhD studies, Dr. Gao demonstrated that insulin-like 
growth factor-binding protein 2 (IGFBP2) is a potential 
oncogene that contributes to malignant behaviors of pan-
creatic ductal adenocarcinoma. The exciting results were 
reported in Cancer Research. Currently, Dr. Gao is 
focused on mutual regulation of hypoxia-inducible fac-
tor-1 (HIF-1) and IGFBP2 in exosome secretion from 
pancreatic cancer cells. As an oncology surgeon special-
izing in pancreatic cancer, he continues to work with his 
colleagues on an IGFBP2 project in pancreatic cancer as 
well as being an active member of the surgery team. Dr. 
Gao has been a key research investigator on two research 
projects sponsored by the National Natural Science 
Foundation of China.
Fig. 1 The ceremony of the 6th USCACA–AFCR Scholar Awards was held in Guangzhou on December 2, 2016. Awards were presented by Dr. Wei 
Zhang from the USCACA Executive Committee. From left to right Dr. Wei Zhang (Wake Forest University), Dr. Ruihua Xu (the President of Sun Yat‑sen 
University Cancer Center), Dr. Xiang Zhou, Dr. Song Gao, Dr. Boris Pasche (Director of Wake Forest Baptist Comprehensive Cancer Center), Dr. Jianhua 
Zhou, and Dr. Zhongzhen Guan (a former president of Sun Yat‑sen University Cancer Center). USCACA, the US Chinese Anti‑Cancer Association; 
AFCR, the Asian Fund for Cancer Research
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Dr. Jianhua Zhou joined 
Prof. Juergen K. Will-
mann’s laboratory in the 
Department of Radiology, 
Stanford University, Stan-
ford, California, USA in 
November 2014. During 
his tenure at Stanford, he 
investigated whether 
three-dimensional ultra-
sound molecular imaging 
(3D USMI) of vascular 
endothelial growth factor 
receptor 2 (VEGFR2)/
kinase insert domain receptor (KDR) expression could 
accurately gauge longitudinal treatment responses to 
anti-angiogenic therapy in responding versus non-
responding colon cancer mouse models. Dr. Zhou dem-
onstrated that tumors in these models exhibited 
differential patterns of VEGFR2-targeted 3D USMI sig-
nals during anti-angiogenic therapy. In responding 
tumors, the VEGFR2 signals decreased as soon as 24  h 
after initiation of therapy, whereas in non-responding 
tumors there was no change in signals at any time point. 
The early decrease in VEGFR2 signals was highly predic-
tive of treatment outcome at the end of therapy. His find-
ings suggest that 3D USMI could be further developed 
for monitoring early treatment changes in cancer 
patients. This work was published in Cancer Research in 
2016. In December 2015, Dr. Zhou returned to Sun Yat-
sen University Cancer Center to continue his career as an 
associate professor. His current research has been funded 
by three grants from the National Natural Science Foun-
dation of China. The goal of his investigations is to pro-
vide noninvasive approaches for early monitoring tumor 
response to chemotherapy in clinic.
Dr. Xiang Zhou is currently 
an associate professor at 
Shanghai Cancer Center 
and Institutes of Biomedical 
Sciences of Fudan Univer-
sity. He received his BS 
degree in biotechnology in 
2004 and Ph.D. degree in 
genetics in 2009 from 
Wuhan University, Wuhan, 
Hubei, China. In 2009, Dr. 
Zhou joined Dr. Hua Lu’s 
laboratory at Indiana Uni-
versity School of Medicine, 
Indianapolis, Indiana, USA as a postdoctoral fellow and, 
later on, he moved to Tulane University School of Medicine, 
New Orleans, Louisiana, USA with Dr. Lu as a research 
scientist. Dr. Zhou’s research was to understand the mecha-
nisms underlying the regulation of p53 and c-Myc. One of 
his research projects was to elucidate the mechanism of 
ribosomal (nucleolar) stress-mediated tumor suppression. 
Dr. Zhou demonstrated that, in response to ribosomal 
stress, several ribosomal proteins can activate p53 or p73 by 
inhibiting negation of mouse double minute 2 (MDM2) and 
inactivate c-Myc through their direct interaction as well as 
microRNA pathways. These studies were separately pub-
lished in Oncogene, Cell Death & Differentiation, and Jour-
nal of Biological Chemistry. In addition, Dr. Zhou and his 
colleagues identified two p53-inducible genes, NGFR and 
PHLDB3, which promoted chemoresistance by suppressing 
p53 activity as feedback regulators. These results were pub-
lished in Elife and Nature Communications, respectively. Dr. 
Zhou’s current research interests focus on the translational 
study of ribosomal stress-induced tumor suppression and 
dissection of the oncogenic mechanism of mutant p53 dur-
ing tumorigenesis.
About US Chinese Anti‑Cancer Association 
(USCACA)
USCACA is a non-profit professional organization 
founded in 2009 (http://www.uscaca.org/). With mem-
bers from academia, industry, and government, USCACA 
facilitates collaborations among cancer researchers and 
physicians in the US and China. We currently focus on 
expediting novel cancer drug development by fostering 
clinical trial networks, sharing expert medical practices 
and knowledge of clinical trials, and providing educa-
tion and training opportunities. USCACA collaborates 
with Chinese Anti-Cancer Association (CACA), Chinese 
Society for Clinical Oncology (CSCO), Chinese Medi-
cal Association (CMA), and Chinese Society for Oncol-
ogy (CSO), as well as other professional associations. 
Our mandate is to improve cancer treatment through 
research, education, and collaboration.
About the Asian Fund for Cancer Research (AFCR)
The AFCR is a non-profit organization committed to 
curing cancers that have significant impacts on Asian 
populations. Headquartered in Hong Kong, AFCR is 
uniquely positioned to implement in Asia the newest 
cancer research discoveries and technologies around the 
world, investigate the distinct causes of cancer in Asian 
populations through innovative genetic and molecular 
researches, and develop more effective therapies tailored 
to Asian cancer patients. AFCR is dedicated to bridging 
the scientific and educational gaps in cancer research and 
cancer prevention between Asian countries and the rest 
of the world through promoting, coordinating, and fund-
ing international collaborations in cancer research and 
public education.
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The common goal of USCACA and AFCR
The common goal of USCACA and AFCR is to conquer 
cancer by improving our understanding of cancer and 
providing more efficacious and safe treatment options 
to cancer patients through expediting novel cancer drug 
development that stimulates the translation of labora-
tory discoveries into novel cancer treatments. We aim to 
encourage the translation of laboratory discoveries into 
novel therapeutic treatments of cancer patients, foster 
collaborations in scientific discovery, cancer drug devel-
opment, and clinical treatments, and share expert knowl-
edge and medical practices between China and the US. 
The USCACA–AFCR Scholarship Program provides 
a unique opportunity for junior Chinese scholars who 
have an interest in advancing their basic, translational, 
and clinical knowledge and skills in cancer research. It 
also allows these young scholars to establish long-term 
collaborations with leading cancer researchers in the US 
who can support their continued work and future success 
in China.
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